Amplia reshapes board for next phase of cancer drug push
Amplia Therapeutics appointed Jane Bell AM as chairman as the company moves to advance its cancer drug development. The leadership change comes after encouraging results from the phase 1b/2a ACCENT trial of narmafotinib, which showed a 36% objective response rate in advanced pancreatic cancer patients. Amplia aims for regulatory engagement with the FDA in 2026.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 30 Jun 2026, 05:56 UTC · Updated 30 Jun 2026, 06:01 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections
Trending
- 'It's who we are': Albanese issues impassioned defence of multiculturalism
- Cody Gakpo and partner Noa van der Bi announce miscarriage of son
- Court returns proceeds of house sale seized from convicted paedophile
- Abigail Velez apologizes for controversial comment about Bosnia during broadcast
- Former CFMEU chief pleads for drug trafficker tied to Big Build corruption
- Katrina Kroetch showcases women's magic talent at Melbourne Magic Festival